Iradimed Corp (IRMD)
NASDAQ:IRMD
Want to see IRMD full AI Analyst Report?
IRMD Stock Chart & Stats
$76.42
$0.29(0.51%)
At close: 4:00 PM EST
$76.42
$0.29(0.51%)
Day’s Range― - ―
52-Week Range$50.31 - $107.90
Previous CloseN/A
Volume15.52K
Average Volume (3M)86.64K
Market Cap
$1.09B
Enterprise Value$1.04B
Total Cash (Recent Filing)$56.37M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)52.9
Beta0.64
Next Earnings
Jul 30, 2026EPS Estimate
0.45Next Dividend Ex-DateN/A
Dividend Yield1.22%
Share Statistics
EPS (TTM)1.86
Shares Outstanding12,783,035
10 Day Avg. Volume107,754
30 Day Avg. Volume86,645
Financial Highlights & Ratios
PEG Ratio3.35
Price to Book (P/B)13.08
Price to Sales (P/S)14.77
P/FCF Ratio72.03
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue12.07
Enterprise Value/Gross Profit15.70
Enterprise Value/Ebitda34.08
Forecast
1Y Price Target
$118.67Price Target Upside55.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)2.02
Revenue Forecast (FY)$92.28M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins near the mid-70s% imply durable pricing power and product differentiation in MRI-safe devices. High product-level margins provide a structural buffer against input cost inflation, fund R&D and sales efforts, and underpin persistent operating leverage as revenue scales, supporting long-term profitability.
Conservative Balance SheetEffectively zero debt and strong ROE (~22–24%) give IRadimed financial flexibility to fund the 3870 ramp, absorb short-term working-capital swings, and invest in go-to-market or R&D without refinancing risk. This capital conservatism reduces solvency risk and preserves optionality over multi-quarter cycles.
Large Replacement Market + 3870 ASP UpliftA multi-thousand channel replacement addressable market combined with a 10–14% expected ASP uplift from the 3870 creates a structural revenue and margin opportunity. If hospital replacement cycles and adoption follow management targets, recurring disposables, service and higher ASPs can sustainably increase revenue depth and lifetime customer value.
Bears Say
US Revenue ConcentrationHeavy reliance on the U.S. market leaves growth and cash generation exposed to U.S. hospital purchasing cycles, reimbursement shifts, or budget constraints. Limited near-term international diversification amplifies cyclical sensitivity and makes multi-quarter revenue targets dependent on a single geography's capital spending patterns.
Transition & Inventory RiskManaging legacy stock while ramping a new platform creates inventory obsolescence, stocking and channel timing risks. Operational missteps could force write-downs, distort working capital, or create channel shortages that delay replacements. These execution risks can erode margins and cash conversion for multiple quarters during the transition.
Delayed International ClearancesStaggered regulatory timelines postpone international contribution and prolong geographic concentration. Delays compress near-term addressable market, slow scale economies on manufacturing, and extend the period before international disposables/maintenance revenue offsets U.S. cyclicality, making 2026 growth more execution-dependent.
Iradimed News
IRMD FAQ
What was Iradimed Corp’s price range in the past 12 months?
Iradimed Corp lowest stock price was $50.31 and its highest was $107.90 in the past 12 months.
What is Iradimed Corp’s market cap?
Iradimed Corp’s market cap is $1.09B.
When is Iradimed Corp’s upcoming earnings report date?
Iradimed Corp’s upcoming earnings report date is Jul 30, 2026 which is in 85 days.
How were Iradimed Corp’s earnings last quarter?
Iradimed Corp released its earnings results on May 01, 2026. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.445 by $0.045.
Is Iradimed Corp overvalued?
According to Wall Street analysts Iradimed Corp’s price is currently Undervalued.
Does Iradimed Corp pay dividends?
Iradimed Corp pays a Monthly dividend of $0.5 which represents an annual dividend yield of 1.22%. See more information on Iradimed Corp dividends here
What is Iradimed Corp’s EPS estimate?
Iradimed Corp’s EPS estimate is 0.45.
How many shares outstanding does Iradimed Corp have?
Iradimed Corp has 12,783,035 shares outstanding.
What happened to Iradimed Corp’s price movement after its last earnings report?
Iradimed Corp reported an EPS of $0.49 in its last earnings report, beating expectations of $0.445. Following the earnings report the stock price went up 4.446%.
Which hedge fund is a major shareholder of Iradimed Corp?
Currently, no hedge funds are holding shares in IRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iradimed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$118.67 (55.28% Upside)
$118.67 (55.28% Upside)
Blogger Sentiment
Bullish
IRMD Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 11.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $100.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days <0.1%
Last 30 Days <0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
83.69%
12-Months-Change
Fundamentals
Return on Equity
23.83%
Trailing 12-Months
Asset Growth
10.63%
Trailing 12-Months
Company Description
Iradimed Corp
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
IRMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a largely positive outlook driven by strong Q1 financial results (13% revenue growth, 33% operating income growth, double-digit net income improvement), healthy margins, substantial cash generation, and an encouraging early 3870 product launch with higher-than-expected ASP and quad-system demand. Near-term headwinds are primarily transitional and execution-related: a planned conservative manufacturing ramp (130–135 3870s in Q2) leads to guidance showing a modest Q2 revenue dip versus Q1, and there are temporary tax and R&D expense effects. These lowlights appear manageable relative to the magnitude of the reported financial improvements and the sizeable replacement opportunity for the 3870, so positive momentum is the dominant theme.View all IRMD earnings summariesIRMD Stock 12 Month Forecast
Average Price Target
$118.67
▲(55.28% Upside)
Technical Analysis
Ownership Overview
35.12% Insiders
12.71% Mutual Funds
2.29% Other Institutional Investors
40.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---